Literature DB >> 9433879

Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor.

X Su1, T Zhou, P Yang, C K Edwards, J D Mountz.   

Abstract

OBJECTIVE: To determine the effects of anti-tumor necrosis factor (anti-TNF) therapy in the inflammatory and autoimmune disease in motheaten (me/me) mice, which exhibit a Fas apoptosis signaling defect.
METHODS: Arthritis, pneumonitis, and mortality were analyzed in me/me mice treated with a novel, soluble, dimeric TNF receptor I (sTNFRI) molecule capable of high-affinity binding and neutralization of TNFalpha.
RESULTS: Soluble TNFRI reduced serum levels of TNFalpha and led to a 2-fold increase in the lifespan of me/me mice, compared with the control treatment group. The treatment also reduced the development of the "motheaten" skin patches and alleviated pneumonitis and inflammatory lesions in the extremities of me/me mice compared with controls. However, the serum levels of IgM and IgM anti-double-stranded DNA autoantibody were comparable to those of untreated control mice.
CONCLUSION: TNFalpha is an important cytokine involved in the pathogenesis of inflammatory disease in me/me mice, resulting in tissue damage and early mortality. Therapies directed at blocking TNF/TNFR interactions, such as the sTNFRI used in these experiments, may be effective in diseases associated with apoptosis defects leading to overutilization of the TNF/TNFR pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9433879     DOI: 10.1002/1529-0131(199801)41:1<139::AID-ART17>3.0.CO;2-T

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  20 in total

Review 1.  Tumour necrosis factor and other cytokines in murine lupus.

Authors:  A N Theofilopoulos; B R Lawson
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update.

Authors:  M W Davis; U Feige; A M Bendele; S W Martin; C K Edwards
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 3.  Tyrosine phosphatase SHP-1 in allergic and anaphylactic inflammation.

Authors:  Zhou Zhu; Sun Young Oh; You Sook Cho; Li Zhang; Yoon-Keun Kim; Tao Zheng
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

4.  Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger.

Authors:  Ben A Croker; Brian R Lawson; Sophie Rutschmann; Michael Berger; Celine Eidenschenk; Amanda L Blasius; Eva Marie Y Moresco; Sosathya Sovath; Louise Cengia; Leonard D Shultz; Argyrios N Theofilopoulos; Sven Pettersson; Bruce Alan Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-19       Impact factor: 11.205

5.  Prevention and treatment of lethal murine endotoxemia by the novel immunomodulatory agent MFP-14.

Authors:  F Nicoletti; R Di Marco; P Sacerdote; P Meroni; K Mangano; C Edwards; A Bartorelli; K Bendtzen; A Panerai
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 6.  PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.

Authors:  C K Edwards
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

7.  The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study.

Authors:  Hussein Kadhem Al-Hakeim; Abbas F Almulla; Michael Maes
Journal:  Neurotox Res       Date:  2020-01-08       Impact factor: 3.911

8.  Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.

Authors:  Seyed Mostafa Monzavi; Aida Alirezaei; Zhaleh Shariati-Sarabi; Jalil Tavakol Afshari; Mahmoud Mahmoudi; Banafsheh Dormanesh; Faezeh Jahandoost; Ali Reza Khoshdel; Ali Etemad Rezaie
Journal:  Inflammopharmacology       Date:  2018-07-10       Impact factor: 4.473

9.  The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.

Authors:  Wenpu Zhao; Seth G Thacker; Jeffrey B Hodgin; Hongyu Zhang; Jeffrey H Wang; James L Park; Ann Randolph; Emily C Somers; Subramaniam Pennathur; Matthias Kretzler; Frank C Brosius; Mariana J Kaplan
Journal:  J Immunol       Date:  2009-07-20       Impact factor: 5.422

Review 10.  TNFalpha blockade in human diseases: mechanisms and future directions.

Authors:  Maida Wong; David Ziring; Yael Korin; Sheetal Desai; Sungjin Kim; Jan Lin; David Gjertson; Jonathan Braun; Elaine Reed; Ram Raj Singh
Journal:  Clin Immunol       Date:  2007-10-03       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.